Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.1K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.1K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
Overview of Skeletal Muscle01:15

Overview of Skeletal Muscle

17.1K
Skeletal muscles are composed of a bundle of muscle fibers and are attached to bones through tendons. Each skeletal muscle fiber is a single muscle cell. The sarcolemma, the plasma membrane of a skeletal muscle cell, consists of a lipid bilayer and glycocalyx that supports muscle fibers. The sarcolemma extends into the muscle cells to form tubular structures called transverse or T-tubules. Each side of the T-tubules consists of a membrane-bound structure called the sarcoplasmic reticulum,...
17.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitrous oxide abuse prevalence, mechanisms, treatments and prevention.

Current medical research and opinion·2026
Same author

Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.

The Annals of pharmacotherapy·2026
Same author

Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk.

The Annals of pharmacotherapy·2026
Same author

Correction: Use of SGLT2 Inhibitors in Pediatric Heart Failure: A Multi-Eenter Study.

Pediatric cardiology·2025

Related Experiment Video

Updated: Mar 29, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

5.2K

Effect of statins on skeletal muscle function.

Beth A Parker1, Jeffrey A Capizzi, Adam S Grimaldi

  • 1Division of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT, USA.

Circulation
|November 28, 2012
PubMed
Summary

High-dose atorvastatin did not impair muscle strength or exercise capacity in healthy individuals. However, statins did increase muscle complaints and mild muscle injury, suggesting further research is needed.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K

Related Experiment Videos

Last Updated: Mar 29, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

5.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

12.4K

Area of Science:

  • Cardiology
  • Neurology
  • Exercise Physiology

Background:

  • Clinicians often suspect statins cause muscle pain, but clinical trials have not consistently shown this.
  • The impact of statins on skeletal muscle function and performance requires further investigation.

Purpose of the Study:

  • To evaluate the effects of high-dose atorvastatin on skeletal muscle function and performance in healthy, statin-naive individuals.
  • To assess whether atorvastatin impacts muscle strength, exercise capacity, and creatine kinase levels.

Main Methods:

  • The STOMP study involved 420 healthy, statin-naive subjects receiving atorvastatin 80 mg or placebo for 6 months.
  • Measurements included creatine kinase, exercise capacity, muscle strength, and symptom assessment before and after treatment.

Main Results:

  • Atorvastatin increased average creatine kinase levels (P<0.0001) but did not significantly alter muscle strength or exercise capacity.
  • More subjects on atorvastatin reported myalgia (19 vs. 10; P=0.05) compared to placebo.
  • Myalgic subjects on atorvastatin showed decreased muscle strength in some variables, but this was not statistically significant compared to placebo.

Conclusions:

  • High-dose atorvastatin for 6 months does not reduce muscle strength or exercise performance in healthy subjects.
  • The study confirms that statins can increase muscle complaints (myalgia) and cause mild muscle injury, evidenced by elevated creatine kinase.
  • Further research is recommended to explore the effects of prolonged high-dose statin use on muscle health.